The Zhitong Finance App learned that, according to the Hong Kong Stock Exchange's disclosure on March 31, Shaanxi McAote Technology Co., Ltd. (abbreviation: McAuto) has once again submitted a listing application to the main board of the Hong Kong Stock Exchange, with CCB International and China Merchants Securities International as co-sponsors. The company submitted a statement to the Hong Kong Stock Exchange on September 29, 2025. According to the prospectus, the company's core product, MT1013, is a self-developed phase III dual-target receptor agonist polypeptide that can simultaneously target CaSR and OGP receptors. It is mainly designed to treat secondary hyperparathyroidism, and has the potential to expand to other indications (such as abnormal mineral and bone metabolism (CKD-MBD) in chronic kidney disease with osteoporosis and secondary hyperparathyroidism without dialysis).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.